{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:32:19Z","timestamp":1763134339199,"version":"3.45.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23612-9","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:28:10Z","timestamp":1763134090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of antiemetic regimens in controlling chemotherapy induced nausea and vomiting during hematopoietic stem cell transplantation"],"prefix":"10.1038","volume":"15","author":[{"given":"Paloma","family":"Su\u00e1rez-Casillas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Ciudad-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Antonia","family":"P\u00e9rez-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Bl\u00e1zquez-Go\u00f1i","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Manuel Mart\u00edn","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila Abdel-Kader","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"6","key":"23612_CR1","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1634\/theoncologist.2018-0140","volume":"24","author":"T Yokoe","year":"2019","unstructured":"Yokoe, T. et al. Effectiveness of Antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis. Oncologist. 24(6), e347\u2013e357. https:\/\/doi.org\/10.1634\/theoncologist.2018-0140 (2019).","journal-title":"Oncologist."},{"key":"23612_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102512","volume":"115","author":"M Filetti","year":"2023","unstructured":"Filetti, M. et al. Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis. Cancer Treat Rev. 115, 102512. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102512 (2023).","journal-title":"Cancer Treat Rev."},{"issue":"2","key":"23612_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46989\/001c.94952.PMID:38817311;PMCID:PMC11087001","volume":"6","author":"J Sawyer","year":"2024","unstructured":"Sawyer, J. et al. Prevention and management of acute toxicities from conditioning regimens during hematopoietic stem cell transplantation. Clin Hematol Int. 6(2), 1\u201310. https:\/\/doi.org\/10.46989\/001c.94952.PMID:38817311;PMCID:PMC11087001 (2024).","journal-title":"Clin Hematol Int."},{"issue":"18 Suppl","key":"23612_CR4","first-page":"S398","volume":"24","author":"SA Soefje","year":"2018","unstructured":"Soefje, S. A. Strategies to improve CINV outcomes in managed care. Am J Manag Care. 24(18 Suppl), S398\u2013S404 (2018).","journal-title":"Am J Manag Care."},{"key":"23612_CR5","unstructured":"National Comprehensive Cancer Network (NCCN). Antiemesis guidelines v2.2023. Available at: www.nccn.org. Accessed June, 2023."},{"issue":"28","key":"23612_CR6","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh, P. J. et al. Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 35(28), 3240\u20133261. https:\/\/doi.org\/10.1200\/JCO.2017.74.4789 (2017).","journal-title":"J Clin Oncol."},{"issue":"1","key":"23612_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","volume":"27","author":"Y Razvi","year":"2019","unstructured":"Razvi, Y. et al. ASCO, NCCN, MASCC\/ESMO: A comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 27(1), 87\u201395. https:\/\/doi.org\/10.1007\/s00520-018-4464-y (2019).","journal-title":"Support Care Cancer."},{"issue":"14","key":"23612_CR8","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari, R. M. & Aapro, M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 374(14), 1356\u20131367. https:\/\/doi.org\/10.1056\/NEJMra1515442 (2016).","journal-title":"N Engl J Med."},{"issue":"1","key":"23612_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00520-023-08224-1.PMID:38105286;PMCID:PMC10725845","volume":"32","author":"BL Rapoport","year":"2023","unstructured":"Rapoport, B. L. et al. 2023 updated MASCC\/ESMO consensus recommendations: Prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 32(1), 36. https:\/\/doi.org\/10.1007\/s00520-023-08224-1.PMID:38105286;PMCID:PMC10725845 (2023).","journal-title":"Support Care Cancer."},{"issue":"3","key":"23612_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s44228-022-00012-8","volume":"4","author":"S Yuda","year":"2022","unstructured":"Yuda, S., Fuji, S., Savani, B. & Gatwood, K. S. Antiemetic strategies in patients who undergo hematopoietic stem cell transplantation. Clin Hematol Int. 4(3), 89\u201398. https:\/\/doi.org\/10.1007\/s44228-022-00012-8 (2022).","journal-title":"Clin Hematol Int."},{"key":"23612_CR11","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00520-021-06495-0","volume":"30","author":"N Di Renzo","year":"2022","unstructured":"Di Renzo, N., Musso, M. & Scim\u00e8, R. Efcacy and safety of netupitant\/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin\u2019s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation. Support Care Cancer 30, 1521\u20131527. https:\/\/doi.org\/10.1007\/s00520-021-06495-0 (2022).","journal-title":"Support Care Cancer"},{"issue":"2","key":"23612_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00520-016-3445-2","volume":"25","author":"M Nakagaki","year":"2017","unstructured":"Nakagaki, M., Barras, M., Curley, C., Butler, J. P. & Kennedy, G. A. A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer. 25(2), 607\u2013613. https:\/\/doi.org\/10.1007\/s00520-016-3445-2 (2017).","journal-title":"Support Care Cancer."},{"issue":"9","key":"23612_CR13","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.clml.2017.06.012","volume":"17","author":"S Trifilio","year":"2017","unstructured":"Trifilio, S. et al. Olanzapine reduces chemotherapy-induced nausea and vomiting compared with aprepitant in myeloma patients receiving high-dose melphalan before stem cell transplantation: A retrospective study. Clin Lymphoma Myeloma Leuk. 17(9), 584\u2013589. https:\/\/doi.org\/10.1016\/j.clml.2017.06.012 (2017).","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"4","key":"23612_CR14","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1177\/1078155219879215","volume":"26","author":"T Monson","year":"2020","unstructured":"Monson, T., Greer, D., Kreikemeier, E. & Liewer, S. Olanzapine as a rescue antiemetic in hematopoietic stem cell transplant. J Oncol Pharm Pract. 26(4), 918\u2013922. https:\/\/doi.org\/10.1177\/1078155219879215 (2020).","journal-title":"J Oncol Pharm Pract."},{"issue":"8","key":"23612_CR15","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s00277-022-04877-w","volume":"101","author":"P Ye","year":"2022","unstructured":"Ye, P. et al. Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: A retrospective study. Ann Hematol. 101(8), 1835\u20131841. https:\/\/doi.org\/10.1007\/s00277-022-04877-w (2022).","journal-title":"Ann Hematol."},{"key":"23612_CR16","unstructured":"-PRO-CTCAE\u2122 Measurement system. Available in: https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/instruments\/pro-ctcae\/pro-ctcae_spanish.pdf"},{"issue":"7","key":"23612_CR17","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1007\/s00520-015-3062-5","volume":"24","author":"B Arnold","year":"2016","unstructured":"Arnold, B. et al. PRO-CTCAE Spanish translation and linguistic validation study group. Linguistic validation of the Spanish version of the national cancer institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Support Care Cancer. 24(7), 2843\u20132851. https:\/\/doi.org\/10.1007\/s00520-015-3062-5 (2016).","journal-title":"Support Care Cancer."},{"issue":"10","key":"23612_CR18","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.bbmt.2018.06.005","volume":"24","author":"AB Clemmons","year":"2018","unstructured":"Clemmons, A. B. et al. Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: The FOND-O trial. Biol Blood Marrow Transplant. 24(10), 2065\u20132071. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.005 (2018).","journal-title":"Biol Blood Marrow Transplant."},{"key":"23612_CR19","first-page":"213","volume":"16","author":"ED Agura","year":"1995","unstructured":"Agura, E. D., Brown, M. C., Schaffer, R., Donaldson, G. & Shen, D. D. Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant. Bone Marrow Transplant. 16, 213\u2013222 (1995).","journal-title":"Bone Marrow Transplant."},{"key":"23612_CR20","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1016\/S0041-1345(00)01841-8","volume":"32","author":"JF Lacerda","year":"2000","unstructured":"Lacerda, J. F. et al. Randomized trial of ondansetron, granisetron, and tropisetron in the prevention of acute nausea and vomiting. Transplant Proc. 32, 2680\u20132681 (2000).","journal-title":"Transplant Proc."},{"key":"23612_CR21","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/annonc\/mdq457","volume":"22","author":"SA Giralt","year":"2011","unstructured":"Giralt, S. A. et al. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol. 22, 939\u2013946 (2011).","journal-title":"Ann Oncol."},{"issue":"3","key":"23612_CR22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1177\/1078155215585190","volume":"22","author":"SM Clark","year":"2016","unstructured":"Clark, S. M. et al. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. J Oncol Pharm Pract. 22(3), 416\u2013422. https:\/\/doi.org\/10.1177\/1078155215585190 (2016).","journal-title":"J Oncol Pharm Pract."},{"issue":"5","key":"23612_CR23","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/ejh.14282","volume":"113","author":"N B\u00e1ez-Guti\u00e9rrez","year":"2024","unstructured":"B\u00e1ez-Guti\u00e9rrez, N., Su\u00e1rez-Casillas, P., P\u00e9rez-Moreno, M. A., Bl\u00e1zquez-Go\u00f1i, C. & Abdelkader-Mart\u00edn, L. Antiemetic prophylaxis regimens in haematologic malignancies patients undergoing a hematopoietic stem cell transplantation. Which is the best standard of care? A systematic review. Eur J Haematol. 113(5), 564\u2013575. https:\/\/doi.org\/10.1111\/ejh.14282 (2024).","journal-title":"Eur J Haematol."},{"key":"23612_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbmt.2012.07.019","volume":"19","author":"PJ Stiff","year":"2013","unstructured":"Stiff, P. J. et al. Prevention of nausea and vomiting associated with stem cell transplant: Results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 19, 49-55.e1 (2013).","journal-title":"Biol Blood Marrow Transplant"},{"key":"23612_CR25","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41409-018-0106-8","volume":"53","author":"J Bubalo","year":"2018","unstructured":"Bubalo, J., Mulverhill, K., Meyers, G., Hayes-Lattin, B. & Maziarz, R. A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT). Bone Marrow Transplant 53, 1010\u20131018 (2018).","journal-title":"Bone Marrow Transplant"},{"key":"23612_CR26","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1200\/JCO.2013.55.0095","volume":"32","author":"T Schmitt","year":"2014","unstructured":"Schmitt, T. et al. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: Results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32, 3413\u20133420 (2014).","journal-title":"J Clin Oncol"},{"key":"23612_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000371523","volume":"89","author":"A Svanberg","year":"2015","unstructured":"Svanberg, A. & Birgeg\u00e5rd, G. Addition of aprepitant (Emend\u00ae) to standard antiemetic regimen continued for 7 days after chemotherapy for stem cell transplantation provides significant reduction of vomiting. Oncology 89, 31\u201336 (2015).","journal-title":"Oncology"},{"issue":"5","key":"23612_CR28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari, R. M., Gray, S. E. & Kerr, A. C. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A randomized phase III trial. J Support Oncol. 9(5), 188\u2013195. https:\/\/doi.org\/10.1016\/j.suponc.2011.05.002 (2011).","journal-title":"J Support Oncol."},{"issue":"1","key":"23612_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1756-9966-28-131","volume":"28","author":"L Tan","year":"2009","unstructured":"Tan, L. et al. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res. 28(1), 131. https:\/\/doi.org\/10.1186\/1756-9966-28-131 (2009).","journal-title":"J Exp Clin Cancer Res."},{"issue":"2","key":"23612_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari, R. M. et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 375(2), 134\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa1515725 (2016).","journal-title":"N Engl J Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23612-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23612-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23612-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:28:11Z","timestamp":1763134091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23612-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23612"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23612-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39975"}}